Christopher G. Azzoli
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 100
- Lung Cancer Diagnosis and Treatment 51
- Oncology top 0.2%
- Lung Cancer Research Studies 54
- Peptidase Inhibition and Analysis 13
- Colorectal Cancer Treatments and Studies 13
- HER2/EGFR in Cancer Research 12
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 12
- Otorhinolaryngology top 2%
-
- Cancer therapeutics and mechanisms 14
- Co-authors
- Mark G. KrisJohn R. StrawnWilliam PaoSherman BakerThomas J. SmithVincent A. MillerLee M. KrugNaiyer A. Rizvi
- Journals
- Proceedings of the National Academy of Sciences (1 paper)JAMA (1 paper)Journal of Clinical Oncology (52 papers)
- Partner nations
- United StatesAustraliaJapan
In The Last Decade
Christopher G. Azzoli
150 papers receiving 10.0k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Pulmonary and Respiratory Medicine 7.5k
- Oncology 6.0k
- Cancer Research 1.4k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Otorhinolaryngology 176
Countries citing papers authored by Christopher G. Azzoli
This map shows the geographic impact of Christopher G. Azzoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher G. Azzoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher G. Azzoli more than expected).
Fields of papers citing papers by Christopher G. Azzoli
This network shows the impact of papers produced by Christopher G. Azzoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher G. Azzoli. The network helps show where Christopher G. Azzoli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christopher G. Azzoli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 137 | |
| 2 | 2016 | 4 | |
| 3 | 2016 | 18 | |
| 4 | 2015 | 44 | |
| 5 | 2014 | 64 | |
| 6 | 2013 | 176 | |
| 7 | 2013 | 266 | |
| 8 | 2012 | 122 | |
| 9 | 2012 | 99 | |
| 10 | 2011 | 50 | |
| 11 | 2011 | 13 | |
| 12 | 2011 | 68 | |
| 13 | 2010 | 70 | |
| 14 | 2010 | 101 | |
| 15 | 2010 | 74 | |
| 16 | American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancerbreakdown → | 2009 | 752 |
| 17 | 2008 | 202 | |
| 18 | Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC) | 2007 | 1 |
| 19 | 2007 | 11 | |
| 20 | 2007 | 2 |
About Christopher G. Azzoli
Christopher G. Azzoli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 154 papers that have together received 10.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (54 papers), Lung Cancer Diagnosis and Treatment (51 papers), Cancer therapeutics and mechanisms (14 papers), Peptidase Inhibition and Analysis (13 papers), Colorectal Cancer Treatments and Studies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Genomics and Diagnostics (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.5k citations), Oncology (6.0k citations) and Cancer Research (1.4k citations). Christopher G. Azzoli has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Mark G. Kris, John R. Strawn, William Pao, Sherman Baker, Thomas J. Smith, Vincent A. Miller, Lee M. Krug, Naiyer A. Rizvi, David G. Pfister and Sarah Temin. Their work appears in journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.